Starpharma Secures $32 Million as Strong Shareholder Support Fuels Oncology Pipeline
Starpharma Holdings Limited (ASX: SPL) has successfully completed its fully underwritten 1-for-7.5 renounceable entitlement offer, raising $32 million before costs. The offer attracted strong participation, with existing shareholders taking up approximately 99% of their entitlements, including $5.4 million received through the oversubscription facility.
The company expects to issue 56,126,514 new shares on 11 August 2026, with the securities ranking equally with existing shares. Canaccord Genuity is also expected to subscribe for or secure subscriptions for $0.5 million of shortfall shares under the underwriting arrangement. The funds are expected to support Starpharma’s planned Phase 1 clinical program for DEP HER2-Lutetium, including its initial human trials and dose-escalation work, alongside the advancement of other oncology programs within the DEP portfolio. The company said its pipeline has also progressed through strategic partnerships and internal discovery programs over the past year.
Customer Notice:
Nextgen Global Services Pty Ltd trading as Kapitales Research (ABN 89 652 632 561) is a Corporate Authorised Representative (CAR No. 1293674) of Enva Australia Pty Ltd (AFSL 424494). The information contained in this website is general information only. Any advice is general advice only. No consideration has been given or will be given to the individual investment objectives, financial situation or needs of any particular person. The decision to invest or trade and the method selected is a personal decision and involves an inherent level of risk, and you must undertake your own investigations and obtain your own advice regarding the suitability of this product for your circumstances. Please be aware that all trading activity is subject to both profit & loss and may not be suitable for you. The past performance of this product is not and should not be taken as an indication of future performance.
Kapitales Research, Level 13, Suite 1A, 465 Victoria Ave, Chatswood, NSW 2067, Australia | 1800 005 780 | info@kapitales.com.au
x
Daily Dose of Buy, Sell & Hold recommendations before the market opens.
Start Your 7 Days Free Trial Now!
We use cookies to help us improve, promote, and protect our services.
By continuing to use this site, we assume you consent to this.
Read our
Privacy Policy
and
Terms & Conditions
Starpharma Secures $32 Million as Strong Shareholder Support Fuels Oncology Pipeline
Starpharma Holdings Limited (ASX: SPL) has successfully completed its fully underwritten 1-for-7.5 renounceable entitlement offer, raising $32 million before costs. The offer attracted strong participation, with existing shareholders taking up approximately 99% of their entitlements, including $5.4 million received through the oversubscription facility.
The company expects to issue 56,126,514 new shares on 11 August 2026, with the securities ranking equally with existing shares. Canaccord Genuity is also expected to subscribe for or secure subscriptions for $0.5 million of shortfall shares under the underwriting arrangement. The funds are expected to support Starpharma’s planned Phase 1 clinical program for DEP HER2-Lutetium, including its initial human trials and dose-escalation work, alongside the advancement of other oncology programs within the DEP portfolio. The company said its pipeline has also progressed through strategic partnerships and internal discovery programs over the past year.
Customer Notice:
Nextgen Global Services Pty Ltd trading as Kapitales Research (ABN 89 652 632 561) is a Corporate Authorised Representative (CAR No. 1293674) of Enva Australia Pty Ltd (AFSL 424494). The information contained in this website is general information only. Any advice is general advice only. No consideration has been given or will be given to the individual investment objectives, financial situation or needs of any particular person. The decision to invest or trade and the method selected is a personal decision and involves an inherent level of risk, and you must undertake your own investigations and obtain your own advice regarding the suitability of this product for your circumstances. Please be aware that all trading activity is subject to both profit & loss and may not be suitable for you. The past performance of this product is not and should not be taken as an indication of future performance.
Kapitales Research, Level 13, Suite 1A, 465 Victoria Ave, Chatswood, NSW 2067, Australia | 1800 005 780 | info@kapitales.com.au